Cargando…
Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection
Inhaled administration of ethanol in the early stages of COVID-19 would favor its location on the initial replication sites, being able to reduce the progression of the disease and improving its prognosis. Before evaluating the efficacy and safety of this novel therapeutic strategy in humans, its ch...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999202/ https://www.ncbi.nlm.nih.gov/pubmed/33808025 http://dx.doi.org/10.3390/pharmaceutics13030342 |
_version_ | 1783670727537328128 |
---|---|
author | Castro-Balado, Ana Mondelo-García, Cristina Barbosa-Pereira, Letricia Varela-Rey, Iria Novo-Veleiro, Ignacio Vázquez-Agra, Néstor Antúnez-López, José Ramón Bandín-Vilar, Enrique José Sendón-García, Raquel Busto-Iglesias, Manuel Rodríguez-Bernaldo de Quirós, Ana García-Quintanilla, Laura González-Barcia, Miguel Zarra-Ferro, Irene Otero-Espinar, Francisco J. Rey-Bretal, David Lago-Quinteiro, José Ramón Valdés-Cuadrado, Luis Rábade-Castedo, Carlos del Río-Garma, María Carmen Crespo-Diz, Carlos Delgado-Sánchez, Olga Aguiar, Pablo Barbeito-Castiñeiras, Gema Pérez del Molino-Bernal, María Luisa Trastoy-Pena, Rocío Passannante, Rossana Llop, Jordi Pose-Reino, Antonio Fernández-Ferreiro, Anxo |
author_facet | Castro-Balado, Ana Mondelo-García, Cristina Barbosa-Pereira, Letricia Varela-Rey, Iria Novo-Veleiro, Ignacio Vázquez-Agra, Néstor Antúnez-López, José Ramón Bandín-Vilar, Enrique José Sendón-García, Raquel Busto-Iglesias, Manuel Rodríguez-Bernaldo de Quirós, Ana García-Quintanilla, Laura González-Barcia, Miguel Zarra-Ferro, Irene Otero-Espinar, Francisco J. Rey-Bretal, David Lago-Quinteiro, José Ramón Valdés-Cuadrado, Luis Rábade-Castedo, Carlos del Río-Garma, María Carmen Crespo-Diz, Carlos Delgado-Sánchez, Olga Aguiar, Pablo Barbeito-Castiñeiras, Gema Pérez del Molino-Bernal, María Luisa Trastoy-Pena, Rocío Passannante, Rossana Llop, Jordi Pose-Reino, Antonio Fernández-Ferreiro, Anxo |
author_sort | Castro-Balado, Ana |
collection | PubMed |
description | Inhaled administration of ethanol in the early stages of COVID-19 would favor its location on the initial replication sites, being able to reduce the progression of the disease and improving its prognosis. Before evaluating the efficacy and safety of this novel therapeutic strategy in humans, its characterization is required. The developed 65° ethanol formulation is stable at room temperature and protected from light for 15 days, maintaining its physicochemical and microbiological properties. Two oxygen flows have been tested for its administration (2 and 3 L/min) using an automated headspace gas chromatographic analysis technique (HS-GC-MS), with that of 2 L/min being the most appropriate one, ensuring the inhalation of an ethanol daily dose of 33.6 ± 3.6 mg/min and achieving more stable concentrations during the entire treatment (45 min). Under these conditions of administration, the formulation has proven to be safe, based on histological studies of the respiratory tracts and lungs of rats. On the other hand, these results are accompanied by the first preclinical molecular imaging study with radiolabeled ethanol administered by this route. The current ethanol formulation has received approval from the Spanish Agency of Medicines and Medical Devices for a phase II clinical trial for early-stage COVID-19 patients, which is currently in the recruitment phase (ALCOVID-19; EudraCT number: 2020-001760-29). |
format | Online Article Text |
id | pubmed-7999202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79992022021-03-28 Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection Castro-Balado, Ana Mondelo-García, Cristina Barbosa-Pereira, Letricia Varela-Rey, Iria Novo-Veleiro, Ignacio Vázquez-Agra, Néstor Antúnez-López, José Ramón Bandín-Vilar, Enrique José Sendón-García, Raquel Busto-Iglesias, Manuel Rodríguez-Bernaldo de Quirós, Ana García-Quintanilla, Laura González-Barcia, Miguel Zarra-Ferro, Irene Otero-Espinar, Francisco J. Rey-Bretal, David Lago-Quinteiro, José Ramón Valdés-Cuadrado, Luis Rábade-Castedo, Carlos del Río-Garma, María Carmen Crespo-Diz, Carlos Delgado-Sánchez, Olga Aguiar, Pablo Barbeito-Castiñeiras, Gema Pérez del Molino-Bernal, María Luisa Trastoy-Pena, Rocío Passannante, Rossana Llop, Jordi Pose-Reino, Antonio Fernández-Ferreiro, Anxo Pharmaceutics Article Inhaled administration of ethanol in the early stages of COVID-19 would favor its location on the initial replication sites, being able to reduce the progression of the disease and improving its prognosis. Before evaluating the efficacy and safety of this novel therapeutic strategy in humans, its characterization is required. The developed 65° ethanol formulation is stable at room temperature and protected from light for 15 days, maintaining its physicochemical and microbiological properties. Two oxygen flows have been tested for its administration (2 and 3 L/min) using an automated headspace gas chromatographic analysis technique (HS-GC-MS), with that of 2 L/min being the most appropriate one, ensuring the inhalation of an ethanol daily dose of 33.6 ± 3.6 mg/min and achieving more stable concentrations during the entire treatment (45 min). Under these conditions of administration, the formulation has proven to be safe, based on histological studies of the respiratory tracts and lungs of rats. On the other hand, these results are accompanied by the first preclinical molecular imaging study with radiolabeled ethanol administered by this route. The current ethanol formulation has received approval from the Spanish Agency of Medicines and Medical Devices for a phase II clinical trial for early-stage COVID-19 patients, which is currently in the recruitment phase (ALCOVID-19; EudraCT number: 2020-001760-29). MDPI 2021-03-05 /pmc/articles/PMC7999202/ /pubmed/33808025 http://dx.doi.org/10.3390/pharmaceutics13030342 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Castro-Balado, Ana Mondelo-García, Cristina Barbosa-Pereira, Letricia Varela-Rey, Iria Novo-Veleiro, Ignacio Vázquez-Agra, Néstor Antúnez-López, José Ramón Bandín-Vilar, Enrique José Sendón-García, Raquel Busto-Iglesias, Manuel Rodríguez-Bernaldo de Quirós, Ana García-Quintanilla, Laura González-Barcia, Miguel Zarra-Ferro, Irene Otero-Espinar, Francisco J. Rey-Bretal, David Lago-Quinteiro, José Ramón Valdés-Cuadrado, Luis Rábade-Castedo, Carlos del Río-Garma, María Carmen Crespo-Diz, Carlos Delgado-Sánchez, Olga Aguiar, Pablo Barbeito-Castiñeiras, Gema Pérez del Molino-Bernal, María Luisa Trastoy-Pena, Rocío Passannante, Rossana Llop, Jordi Pose-Reino, Antonio Fernández-Ferreiro, Anxo Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection |
title | Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection |
title_full | Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection |
title_fullStr | Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection |
title_full_unstemmed | Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection |
title_short | Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection |
title_sort | development and characterization of inhaled ethanol as a novel pharmacological strategy currently evaluated in a phase ii clinical trial for early-stage sars-cov-2 infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999202/ https://www.ncbi.nlm.nih.gov/pubmed/33808025 http://dx.doi.org/10.3390/pharmaceutics13030342 |
work_keys_str_mv | AT castrobaladoana developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT mondelogarciacristina developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT barbosapereiraletricia developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT varelareyiria developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT novoveleiroignacio developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT vazquezagranestor developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT antunezlopezjoseramon developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT bandinvilarenriquejose developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT sendongarciaraquel developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT bustoiglesiasmanuel developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT rodriguezbernaldodequirosana developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT garciaquintanillalaura developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT gonzalezbarciamiguel developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT zarraferroirene developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT oteroespinarfranciscoj developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT reybretaldavid developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT lagoquinteirojoseramon developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT valdescuadradoluis developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT rabadecastedocarlos developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT delriogarmamariacarmen developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT crespodizcarlos developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT delgadosanchezolga developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT aguiarpablo developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT barbeitocastineirasgema developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT perezdelmolinobernalmarialuisa developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT trastoypenarocio developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT passannanterossana developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT llopjordi developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT posereinoantonio developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection AT fernandezferreiroanxo developmentandcharacterizationofinhaledethanolasanovelpharmacologicalstrategycurrentlyevaluatedinaphaseiiclinicaltrialforearlystagesarscov2infection |